Phi Pharma SA

Phi Pharma SA is a pharmaceutical company focused on developing and manufacturing innovative products for oncology and chronic disease management, utilizing advanced drug delivery systems to improve treatment efficacy and reduce side effects. Founded in 2012, Phi Pharma SA is based in Sion, Switzerland. The company specializes in the development of pharmaceutical products specifically targeting oncology and chronic diseases. The most recent funding round occurred in December 2016, during which Phi Pharma raised CHF 3.

7 million in Series A financing from unspecified investors. The CEO, Franco Merckling, leads the company, which has completed a total of one deal as of the latest available data. Phi Pharma specializes in the development and manufacturing of innovative pharmaceutical products designed to address specific medical needs, particularly within the fields of oncology and chronic disease management. Their core offerings include a range of targeted therapies that leverage advanced drug delivery systems, aiming to enhance efficacy while minimizing side effects.

The company caters to a diverse clientele, including healthcare providers, hospitals, and specialty clinics, focusing on markets in Europe and North America. Phi Pharma’s products are primarily used by healthcare professionals to treat patients with complex health conditions, illustrating their commitment to improving patient outcomes through cutting-edge science and technology. Phi Pharma generates revenue through a structured business model that includes B2B sales to hospitals and healthcare institutions, as well as partnerships with pharmaceutical distributors. Transactions typically occur through direct supply agreements, where the company sells its flagship products, including their proprietary oncology treatments, to healthcare providers.

Pricing structures are based on negotiated contracts that reflect the value and innovation of their pharmaceutical offerings. This approach allows Phi Pharma to maintain a steady revenue stream while ensuring that their products are accessible to a wide range of medical institutions and ultimately, to the patients who benefit from their therapies. Phi Pharma plans to utilize the CHF 3. 7 million raised in the Series A round to support the development of new pharmaceutical products, particularly in oncology.

The company is working on launching several new therapies by the end of 2023, aiming to expand into new markets in Asia and Latin America. This strategic expansion is expected to enhance their presence in these regions and meet growing demand for advanced medical treatments.